Extended-Release Buprenorphine vs. Sublingual Buprenorphine for the Treatment of Opioid Use Disorder

NCT04352166 · clinicaltrials.gov ↗
PHASE2
Phase
SUSPENDED
Status
40
Enrollment
OTHER
Sponsor class

Stopped U.S. Department of Health and Human Services OHRP issued an FWA restriction on NYSPI research that included a pause of human subjects research as of June 23, 2023. This study will resume recruitment after OHRP has approved the resumption of research.

Conditions

Interventions

Sponsor

Frances R Levin

Collaborators